Potent Ventures Inc. ("Potent" or the "Company") (CSE: POT - FSE:0OS2 - OTCQB: POTVF) is pleased to announce that it has closed Non-Brokered private placement (the"Offering") issuing a total of 8,914,999 Units at a price of $0.03 per Unit for aggregate proceeds of$365,000.

Each Unit is comprised of one common share (a "Share") and one a transferrable Share purchase warrant(a "Warrant") of the Company. Each Warrant will entitle the holder to purchase an additional Share at aprice of $0.05 per for a 2-year period after the Closing Date. All the securities issued are subject to a fourmonth and a day hold period from the date of issuance (the "Warrant Expiry Date").

Insiders of the Company purchased an aggregate of 1,000,000 Units in the Poffering. The Company hasrelied on the exemptions from the valuation and minority shareholder approval requirements ofMultilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") contained in sections 5.5(b) and 5.7(1)(a) of MI 61-101 in respect of such insider participation.

This news release does not constitute an offer of securities for sale in the United States. The securitiesbeing offered have not been, nor will they be, registered under the United States Securities Act of 1933,as amended, and such securities may not be offered or sold within the United States absent U.S.registration or an applicable exemption from U.S. registration requirements.

The Company intends to use the proceeds raised from the Offering for General capital purposes XXXXXX

Charlie Lamb, President & CEO, DirectorTelephone: 1(236) 317-2812 - Toll free 1(888) 556-9656E-mail:

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined inthe policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy ofthis release.

Click here to connect with The Gummy Project (CSE:GUMY) to receive an Investor Presentation


Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial

Zeposia was well tolerated, with more than 80% of people staying on therapy through 48 months

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines

New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

  • Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication.
  • Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell's platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.
  • The clinical data, previously reported, included rapid tumor reduction and extended survival.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCell's lead candidate, Bria-IMT™. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCell's approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT™ against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.

"We are thrilled to see the congruence of our scientific insights and the clinical activity of our immunotherapy in advanced breast cancer patients," stated Dr. Williams, BriaCell's President & CEO. "This paper highlights our findings of rapid tumor shrinkage in multiple anatomic locations including difficult to treat sites like the brain. We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers," Dr. Williams added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV –

– If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer

The findings also show majority of HCPs view treating CLL patients as different from treating other cancers - The emotional complexities of this slow-growing cancer point to patient and caregiver need for greater support from HCPs at time of diagnosis

NORTH CHICAGO, Ill. , June 24, 2022 /PRNewswire/ -- AbbVie today shared findings from the newly launched Emotional Impact Report , a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AbbVie Declares Quarterly Dividend

The board of directors of ABBVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.

The cash dividend is payable August 15, 2022 , to stockholders of record at the close of business on July 15, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News